Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shensong Yangxin capsule for mild to moderate systolic heart failure with ventricular premature beats
ChiCTR-TRC-12002061Phase 4Completed
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of shensong yangxin capsule in chronic heart failure (CHF) and Premature ventricular complexes (PVC) (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: 24-hour premature ventricular contraction count. Started Mar 2012; status: completed.
02
Drugs
shensong yangxin capsule
03
Conditions
chronic heart failure (CHF)Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002061.